# *Prunella vulgaris* extract and suramin block SARS-coronavirus *2* virus Spike protein D614 and G614 variants mediated receptor association and virus entry in cell culture system

Zhujun Ao[a], Mable Chan[b], Maggie Jing Ouyang[a], Olukitibi Titus Abiola[a], Mona Mahmoudi[a], Darwyn Kobasa[b], and Xiaojian Yao[a] *

[a] Laboratory of Molecular Human Retrovirology, Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Canada
[b] Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Canada

* To whom correspondence should be addressed to:
X-j. Yao, Dept. of Medical Microbiology, Max Rady College of Medicine,
Faculty of Health Sciences, University of Manitoba, 508-745 Bannatyne Ave, Winnipeg MB R3E 0J9 (xiao-jian.yao@umanitoba.ca)

## Abstract

Until now, no approved effective vaccine and antiviral therapeutic are available for treatment or prevention of SARS-coronavirus 2 (SCoV-2) virus infection. In this study, we established a SCoV-2 Spike glycoprotein (SP), including a SP mutant D614G, pseudotyped HIV-1-based vector system and tested their ability to infect ACE2-expressing cells. This study revealed that a C-terminal 17 amino acid deletion in SCoV-2 SP significantly increases the incorporation of SP into the pseudotyped viruses and enhanced its infectivity, which may be helpful in the design of SCoV2-SP-based vaccine strategies. Moreover, based on this system, we have demonstrated that an aqueous extract from the Chinese herb *Prunella vulgaris* (CHPV) and a compound, suramin, displayed potent inhibitory effects on both wild type and mutant (G614) SCoV-2 SP pseudotyped virus (SCoV-2-SP-PVs)-mediated infection. The 50% inhibitory concentration (IC50) for CHPV and suramin on SCoV-2-SP-PVs are 30, and 40 μg/ml, respectively. To define the mechanisms of their actions, we demonstrated that both CHPV and suramin are able to directly interrupt SCoV-2–SP binding to its receptor ACE2 and block the viral entry step. Importantly, our results also showed that CHPV or suramin can efficiently reduce levels of cytopathic effect caused by SARS-CoV-2 virus (hCoV-19/Canada/ON-VIDO-01/2020) infection in Vero cells. Furthermore, our results demonstrated that the combination of CHPV/suramin with an anti-SARS-CoV-2 neutralizing antibody mediated more potent blocking effect against SCoV2-SP-PVs. Overall, this study provides evidence that CHPV and suramin has anti-SARS-CoV-2 activity and may be developed as a novel antiviral approach against SARS-CoV-2 infection.


Keywords: SARS-CoV-2, spike glycoprotein (SP), pseudovirus, Chinese herb *Prunella vulgaris,* Suramin.

## Introduction

The recent and ongoing outbreak of Coronavirus disease 2019 (COVID-19) has called for serious and urgent global attention [1,2]. The COVID-19 disease is caused by a newly emerged virus strain of Severe Acute Respiratory Syndrome (SARS) known as SARS-CoV-2 [3]. Although the case fatality ratio (CFR) of COVID-19 can only be detected at the end of the outbreak, an estimated global CFR was calculated to be 5.5-5.7% in March 2020, which is shockingly more than seasonal influenza outbreak [4]. While in August 2020, the infection fatality ratio was estimated by WHO to be 0.5-1% [5]. Since the identification of the SARS-CoV-2 sequences [6], extensive efforts worldwide have been focused on the development of vaccine and antiviral drugs against SARS-CoV-2 with the hope to rapidly and efficiently control this new human coronavirus (CoV) infection.

SARS-CoV-2 belongs to a betacoronavirus subfamily that includes enveloped, large and positive-stranded RNA viruses responsible for causing severe respiratory system, gastrointestinal and neurological symptoms [7-10]. The human CoV was first identified in 1960 and constituted about 30% of the causes of the common cold. Among the identified human CoVs are NL63, 229E, OC43, HKU1, SARS-CoV, the Middle East respiratory syndrome (MERS)-CoV, and SARS-CoV-2 [11,12]. A recent study has revealed that SARS-CoV-2 was closely related (88% identity) to two SARS-like CoVs that were isolated from bats in 2018 in China, but it was less related to SARS-CoV (79%) and MERS-CoV (about 50%) [13]. The key determinant for the infectivity of SARS-CoV-2 depends on the host specificity with the viral surface-located trimeric spike (S) glycoprotein (SP), which is commonly cleaved by host proteases into an N-terminal S1 subunit and a membrane-embedded C-terminal S2 region [14]. Recent studies revealed that a SP mutation, Aspartic acid (D) changed to Glycine (G) at amino acid position 614, in the S1 domain has been found in high frequency (65% to 70%) in April to May of 2020, that was associated with an increased viral load and significantly higher transmission rate in infected individuals, but no significant change with disease severity [15]. Following studies also suggested that G614 SP mutant pseudotyped retroviruses infected ACE2-expressing cells markedly more efficiently than those with D614 SP [16].

Up till now, several compounds have been tested in numerous clinical trials, including remdesivir, lopinavir, umifenovir, and hydroxychloroquine [17-21]. Moreover, some *in vitro* research suggested that other drugs such as fusion peptide (EK1), anti-inflammatory drugs (such as hormones and other molecules) could be potentially used in the treatment of SARS-CoV-2 disease (reviewed in [22,23]). However, their safety and efficacy have not been confirmed by clinical trials. Currently, specific antiviral treatment drugs are still not available for SARS-CoV-2 infections [23].

Traditional Chinese medicine holds a unique position among all conventional medicines because of its usage over more than hundreds of years of history. Many aqueous extracts of traditional Chinese medicinal herbs have been proven to have

antiviral activities [24], and most of these are generally of low toxicity, cheap and readily accessible. As an easily accessible and low-cost natural source, they are especially valuable as potential new sources for rapid responses against the ongoing COVID-19 pandemic. *Prunella vulgaris,* widely distributed in China, Europe, northwestern Africa and North America, is known as a self-heal herb and studies have previously found that a water-soluble substance from Chinese Herb *Prunella vulgaris* (CHPV) exhibit significant antiviral activity against HIV, HSV and Ebola virus [25-28]. However, whether CHPV can block SARS-CoV-2 virus infection is unknown. Another compound, Suramin, has also been previously shown to be a potent inhibitor against HIV [29], while the subsequent studies revealed that its inhibitory effects on HIV replication did not correlate with clinical or immunologic improvement [30,31]. A previous study observed that suramin not only substantially reduced viral loads of *chikungunya virus* (CHIKV) in infected mice, but it also ameliorated virus-induced foot lesions in the mice [32]. Recently, Salgado-Benvindo C., *et al.,* reported that Suramin is able to inhibit SARS-CoV-2 infection in cell culture by interfering with early steps of the replication cycle [33].

In this study, we have established a highly sensitive SARS-CoV-2 SP-pseudotyped virus (SCoV-2 SP-PVs) system and investigated the impact of the cytoplasmic tail and a G614 mutant of SP on virus entry ability. We also examined two compounds, CHPV and suramin, for their blocking activities in the SCoV-2 SP-PVs system and SARS-CoV-2 infection, and the antiviral mechanism of their actions. Furthermore, we investigated the synergistic effect of combining anti-SARS-CoV-2 neutralizing antibody (nAb) with CHPV or suramin to enhance their anti-SARS-CoV-2 activity. Overall, this study provides evidence for the first time that CHPV, an aqueous extract from *Prunella vulgaris,* has potent anti- SARS-CoV-2 activity.

## Materials and methods

### Plasmid constructs

The SARS-CoV-2 expressing plasmids (pCAGGS-nCoVSP, pCAGGS-nCoVSPΔC and pCAGGS-nCoVSPΔC$_{G614}$) containing SARS-CoV-2 SP transgene (GenBank accession No. MN908947) or corresponding mutated genes for SPΔC and ΔC$_{G614}$. The SPΔC and ΔC$_{G614,}$ were generated by mutagenic PCR technique. Primers are following: SPΔC-3'primer, 5_GCAGGTACCTAGAATTTGCAGCAGGATCCAC; D614G-5', 5_GCTGTTCTTTATCAGGGTGTTAACTGCACAG; D614G-3', 5_CTGTGCAGTTAACACCCTGATAAAGAACAGC. Mutated genes were cloned into the pCAGGS plasmid and each mutation was confirmed by sequencing. The HIV vector encoding for Gaussia luciferase gene HIV-1 RT/IN/Env tri-defective proviral plasmid (ΔRI/E/Gluc) and the helper packaging plasmid pCMVΔ8.2 encoding for the HIV Gag-Pol plasmids are described previously [26,34].

### Cell culture, antibodies and chemicals

The human embryonic kidney cells (HEK293T) and kidney epithelial cells (VeroE6 and Vero cells (ATCC, CCL-81)) from African green monkey were cultured in Dulbecco's modified Eagle's medium (HEK293T, VeroE6) or Minimum Essential Medium (MEM; Vero). HEK293T expressing ACE2 (293T$_{ACE2}$) was obtained from GeneCopoeia Inc, Rockville, MD. All cell lines were supplemented with 10% fetal bovine serum (FBS), 1X L-Glutamine and 1% penicillin and streptomycin. The rabbit polyclonal antibody against SARS-CoV-2 SP (Cat# 40150-R007) and ACE2 protein (Cat# 40592-T62) were obtained from Sino Biological and anti-HIVp24 monoclonal antibody was described previously [35,36]. The HIV-1 p24 ELISA Kit was obtained from the AIDS Vaccine Program of the Frederick Cancer Research and Development Center. SARS-CoV-2 SP-ACE2 binding ELISA kit (Cat# COV-SACE2-1) was purchased from RayBio. Anti-SARS-CoV-2 neutralizing Antibody (nAb) Human IgG1(SAD-535) was purchased from ACRO Biosystems..

### Preparation and purification of herb extracts of P. vulgaris L (CHPV)

The dried fruitspikes of *P. vulgaris L*. (Labiatae) (Fig. 3A) were first soaked overnight in deionized water at room temperature and then boiled for one hour. Then the cooled supernatant was centrifuged (3000 g, 30 min), filtered through a 0.45 μm cellulose acetate membrane and finally lyophilized, as described previously [25]. The resulting dark brown residue was dissolved in deionized water and stored at -20°C. A single symmetrical peak corresponding to a molecular weight of polysaccharides (approximately 10 kDa) in the aqueous extract from PV was detected by HPLC analysis, as described previously [25]. Suramin (Cat# sc-200833) was purchased from Santa Cruz BioTech and was dissolved in sterile H2O and stored at -20°.

### Virus production, infection and inhibition experiments

SARS-CoV-2 SP or SPΔC pseudotyped viruses (SCoV-2-SP-PVs, SCoV-2-SPΔC-PVs, SCoV-2-SPΔC$_{G614}$-PVs) were produced by transfecting HEK293T cells with pCAGGS-SARS-CoV-2-SP, pCAGGS-SARS-CoV-2-SPΔC, or

pCAGGS-SARS-CoV-2-SP$\Delta C_{G614}$, pCMV$\Delta$8.2 and a Gluc expressing HIV vector $\Delta$RI/E/Gluc. After 48 hrs of transfection, cell culture supernatants were collected and pseudotyped VLPs were purified from the supernatant by ultracentrifugation (32,000 rpm) for 2 hrs. The pelleted VPs were resuspended into RPMI medium and virus titers were quantified using an HIV-1 p24 ELISA assay. The wild type SARS-CoV-2 (hCoV-19/Canada/ON-VIDO-01/2020, GISAID accession# EPI_ISL_425177) was propagated and produced in Vero cells (ATCC, CCL-81).

To investigate the infection ability of SCoV-2-SP-VPs, the same amount of each SCoV-2-SP-PV stock (as adjusted by p24 levels) were used to infect different target cells at 0.4 x $10^5$ cells per well (24 well plate) for 3 hrs and washed. After 48 or 72 hrs, the supernatants were collected and the viral infection rate was evaluated by measuring Gaussia luciferase (Gluc) activity. Briefly, 50ul of Coelenterazine substrate (Nanolight Technology) was added to 20ul of supernatant, mixed well and read in the luminometer (Promega, USA).

To evaluate the anti-SARS-CoV-2 SP-mediated entry activity of CHPV or suramin, various concentrations of herb extract or compound were directly added into target cells at different time points before or after infection, as indicated. After 3hrs of infection at 37°C, the cells were washed once to remove excessive residue viruses/compound and cultured in fresh medium. The anti-SARS-CoV-2 effects of CHPV or suramin were evaluated by measuring the Gluc activity or p24 levels in the supernatant infected cultures.

Efficacy of CHPV or suramin against SARS-CoV-2 (hCoV-19/Canada/ON-VIDO-01/2020, GISAID accession# EPI_ISL_425177) was evaluated in Vero cells. The Vero cells were seeded into 96-well plates and reached a confluency of 90% at the second day. Then each compound was diluted in assay medium (MEM with 1X penicillin-streptomycin) and added to the wells (100 ul/well), followed by adding 100 µL of SARS-CoV-2 at a MOI of 0.01, resulting in a final 1X drug concentrations. As positive controls, wells without drugs were infected with SARS-CoV-2 at the same MOI. Cells were maintained for 72 hrs and then, virus infection induced cytopathic effect (CPE) was monitored in each well.

**Binding Assay**

The inhibitory effect of CHPV or suramin on the interaction of SP-ACE2 was tested with COVID-19 Spike-ACE2 binding assay kit. Briefly, 96-well plate was coated with recombinant SARS-CoV-2 Spike protein. CHPV or suramin was then added to the wells for 10 min followed by adding recombinant human ACE2 protein. After incubation for 3 hours, wells were washed three times and a goat anti-ACE2 antibody that binds to the Spike-ACE2 complex was added followed by applying the HRP-conjugated anti-goat IgG and 3,3',5,5'-tetramethylbenzidine (TMB) substrate. The intensity of the yellow color is then measured at 450 nm.

**Western blot (WB) analyses**

To detect cellular protein ACE2, SARS-CoV-2-SP, or SPΔC in transfected cells or SCoV-2-SP-VPs, transfected $293T_{ACE2}$ cells or VPs were lysed in RIPA buffer, and directly loaded into the 10 % SDS–PAGE gel and the presence of each protein was detected by WB with various corresponding antibodies.

## Results

### Generation of a SARS-CoV-2 SP-pseudotyped HIV-1-based entry system

We first established a sensitive SARS-CoV-2-SP-mediated virus entry system by co-transfecting SARS-CoV-2 SP, a HIV-based vector (ΔRI/ΔEnv/Gluc) in which viral reverse transcriptase/integrase deleted/envelope gene partially deleted and encoded a Gaussia luciferase gene in the *nef* position [34], and a packaging plasmid (pCMVΔR8.2) in HEK293T cells (Fig. 1B). The Gaussia luciferase (Gluc) is a bioluminescent enzyme that can be secreted into the media, enabling the analysis of viral expression by direct measurement of Gluc activity in the supernatant. To do this, we have constructed a full length SP (SARS-CoV-2-SP) and the C-terminal 17 amino acid (aa) deletion SP (SARS-CoV-2-SPΔC) expressing plasmids since previous studies have reported that a carboxyl-terminal truncation of 17 amino acids of SARS SP substantially increased SARS SP-mediated cell-to-cell fusion [37].

To examine the expression and incorporation of SARS-CoV-2 SPs and SPΔC in the cells and the SARS-COV-2-SP pseudotyped viruses (SP-PVs) and SARS-COV-2-SPΔC pseudotyped viruses (SPΔC-PVs), lysates of both virus-producing cells and pseudotyped viruses were analyzed by SDS-PAGE and WB with a mouse anti-SP antibody, as indicated in Fig. 1C. As expected, the HIV capsid Gagp24 protein was detected in all of the cell lysates and the pelleted SP-PVs and SPΔC-PVs pseudoviruses (PVs) by rabbit anti-p24 antibodies (Fig. 1C, lower panel). The SARS-CoV-2 SP including S1/S2 were clearly detected in both SARS-CoV-2-SPs and SARS-CoV-2-SPΔC-transfected cells (Fig. 1C, lane 1). Interestingly our results revealed that virus-incorporation level of SARS-CoV-2-SPΔC were significantly higher than that of SARS-CoV-2-SP (Fig. 1C, compare lane 4 to 3),

To test the infectivity of generated pseudoviruses, we infected 293T-ACE2 cells with serial diluted amounts of pseudoviruses (25, 12.5, 6.25ng of p24) of SP-PVs or SPΔC-PVs for 3 hrs. The Gluc activities or Gagp24 of supernatants from infected cells were measured at 24h, 48h or 72h post infection. The results showed that both SP-PVs and SPΔC-PVs can infect 293T-ACE2 cells and induce an increase of Gluc activity in the supernatants in a dose dependent manner (Fig.1D, left panel). As expected, the infectivity of SPΔC-PVs was significantly higher than that of SP-PVs. The infection of pseudoviruses in $293T_{ACE2}$ cells was further confirmed by detection of the HIVp24 levels in the supernatants of infected cells through ELISA assay (Fig.1D, right panel).

To test whether the infection is ACE2-dependent, we infected various cell lines, including HEK293T, $293T_{ACE2}$ and VeroE6 with SP-PVs and SPΔC-PVs, respectively. The results showed that these pseudoviruses were only able to efficiently infect $293T_{ACE2}$ cells, and not HEK293T or VeroE6 cells (Fig. 2A). In parallel, we only detected high level expression of the SARS-CoV-2 receptor ACE2 in $293T_{ACE2}$ cells, but not in the 293T or Vero E6 cells (Fig. 2B).

In addition, we have generated a $GFP^+$ SARS-CoV-2-SP-mediated virus entry system by cotransfecting SARS-CoV-2 $SP\Delta C_{G614}$, a lentiviral vector that expressing GFP, and the pCMVΔR8.2 in HEK293T cells and produced $SP\Delta C_{G614}$-PVs expressing GFP ($GFP^+$ $SP\Delta C_{G614}$-PVs). After $293T_{ACE2}$ cells were infected with $GFP^+$ $SP\Delta C_{G614}$-PVs, the GFP positive $293T_{ACE2}$ cells were clearly detected under fluorescent microscopy (Fig. 2C)

***2.* SARS-CoV-2 SP G614 variant exhibited stronger receptor association and virus entry.**

Recent sequence analyses revealed a SP mutation, Aspartic acid (D) changed to Glycine (G) at aa position 614, was found in high frequency (65% to 70%) in April to May of 2020, indicating a transmission advantage to D614 [15]. In this study, we have also generated constructs to express SCoV-2-$SP\Delta C_{G614}$ (Fig. 1A,c) and compared its virus entry ability with SCoV-2-SPΔC ($SP\Delta C_{D614}$). Our results showed that SCoV-2-$SP\Delta C_{G614}$ was incorporated into pseudotyped viruses similar to SCoV-2-$SP\Delta C_{D614}$ (Fig. 2D, compare lane 5 to lane 4). However, the SARS-CoV2-$SP\Delta C_{G614}$-pseudotyped viral particles ($SP\Delta C_{G614}$-PVs) mediated approximately 3-fold higher infection than that of $SP\Delta C_{D614}$-PVs (Fig. 2E), suggesting that the $SP_{G614}$ mutation increases SP-mediated viral entry.

**Evaluation of CHPV and Suramin for blocking SARS-CoV2-SP-mediated virus entry**

Next we tested whether CHPV (Fig. 3A) and suramin could block SARS-CoV2 SP-mediated virus entry of 293TACE2 cells. Briefly, 293TACE2 cells were infected with SPΔC-PVs in the presence of different concentrations (25, 50,75, 100 and 200ug/ml) of CHPV (Fig. 3B) or suramin (Fig. 3C), respectively. After 3 hour of infection, the infected cells were washed to remove the viruses and compounds and cultured with fresh medium. At 48 hrs post-infection, the supernatants were collected and the virus-produced Gluc activities were measured for monitoring the infection levels. Consistent with our previous observation [26], we did not detect any CHPV-induced toxic effect on the cells for 3hs exposure, nor for Suramin. Significantly, both CHPV and suramin were able to inhibit SARS-CoV-2-SP-pseudotyped virus infection. The half maximal inhibitory concentration (IC50) of CHPV was 30 ug/ml (Fig.3. B, left panel, while IC50 of Suramin was about 40 ug/ml (Fig.3. B, right panel). The inhibitory effect of CHPV and suramin on a SP mutant pseudotyped virus ($SP\Delta C_{G614}$-PVs) infection was also tested, and results show that $SP\Delta C_{G614}$-PVs infection is also susceptible to CHPV and suramin (Fig. 3C). Furthermore, the SARS-CoV-2-$SP\Delta C_{G614}$ psedotyped GFP+ virus infection was tested in the presence of the two compounds and results showed that the psedotyped GFP+ virus infection was efficiently inhibited by the presence of CHPV and Suramin (Fig. 3D). All of these results demonstrate that both CHPV and suramin exhibit strong inhibitory effect on both $SP\Delta C_{D614}$-PVs and $SP\Delta C_{G614}$-PVs infection.

**Mechanistic analyses of actions of CHPV and Suramin against SARS-CoV2-SP-mediated virus entry**

To gain more insight into the mechanism of how CHPV and Suramin are targeting SARS-CoV-2 SP-PVs infection, each of the drugs (100 μg/ml) was added to $293T_{ACE2}$ cells at various time points during the infection, as indicated in Figure 4. After 48 hrs of infection, the supernatants were collected and measured for virus-expressed GLuc activity. Results showed that a strong inhibitory effect was achieved when cells were pretreated with CHPV or Suramin one hour before infection or when the compounds were present simultaneously with SP-PVs (Fig. 4A and B). Interestingly, even when drug was added at one hr post-infection, CHPV still exhibited nearly 70% inhibition on $SP\Delta C_{G614}$-PVs infection (Fig. 4A), while for Suramin, a lower inhibitory effect (about 30% inhibition) was also observed (Fig. 4B). When CHPV or Suramin was added to culture after 3 hrs of infection, no inhibitory activity on viral infection was observed (Fig. 4A and B). These results suggest that both CHPV and suramin act on the entry step of $SP\Delta C_{G614}$-PVs infection.

To further determine whether CHPV or suramin is targeting the interaction of SARS-CoV2-SP and its receptor, ACE2, , we used an *in vitro* SARS-CoV2-SP/ACE2 binding ELISA assay, as described in Materials and Methods. Additionally, an anti-COVID-19 neutralizing antibody (SAD-S35) [38] was included in parallel. Results revealed that the presence of either CHPV or suramin was able to specifically target and significantly reduce the SARS-CoV2-SP-ACE2 interaction (Fig. 4C and D). It should be noted that the neutralizing antibody (SAD-S35) also showed a strong inhibition on SARS-CoV2-SP/ACE2 interaction (Fig. 4C and D).

**Combination of CHPV and anti-SARS-CoV-2 neutralizing antibody (SAD-S35) mediated more potent blocking effect against SARS-CoV2-SP-PVs.**

As described above, both CHPV and Suramin can inhibit SARS-CoV2-SP/ACE2 interaction and SP-PVs infection. We also tested whether the combination of two compounds could mediate a stronger anti-SARS-CoV-2 activity. Thus, we infected $293T_{ACE2}$ cells with $SP\Delta C_{G614}$-PVs in the presence of a cocktail of CHPV/Suramin (25 μg/mL per compound), or CHPV (50 μg/mL) or Suramin (50 μg/mL) alone. The results showed that in the presence of a cocktail of CHPV/Suramin, $SP\Delta C_{G614}$-PVs was inhibited to 78%, while in the presence of CHPV or suramin alone, inhibition rate was 65% or 40% (Fig. 5A). These results suggest that a combination of these two compounds may be able to achieve more efficient inhibition against SARS-CoV-2 infection.

The anti-SARS-CoV-2 neutralizing antibody (SAD-S35) was also tested and showed a does-dependent neutralizing activity against $SP\Delta C_{G614}$-PVs with an IC50 of 2.4 μg/mL (Fig. 5B). Next, we sought to determine whether the combination of CHPV or Suramin with SAD-S35 could mediate a stronger anti-SARS-CoV-2 activity. Thus, serially diluted SAD-S35 (0.625 to 2.5 μg/ml) was mixed with CHPV (25 μg/mL) or Suramin (25 μg/mL) and added to the $293T_{ACE2}$ cells with $SP\Delta C_{G614}$-PVs

simultaneously. In parallel, same concentrations of SAD-S35 alone were used for comparison. The results show that 1.25 µg/ml of SAD-S35 alone only resulted in an approximately 25% decrease of infection. However, nearly 80% inhibitory effect was achieved when the same concentration of SAD-S35 was combined with CHPV (25µg/ml), or approximately 60% inhibitory effect was achieved when combined with suramin (25µg/ml), while CHPV or suramin alone only mediated 50% or 38% inhibition, respectively (Fig. 5C). All together, the results clearly indicate that a combination of CHPV or suramin with SAD-S35 is able to more potently block SARS-CoV2 infection. By including a low dose of nAb, the amounts of CHPV or Suramin needed to achieve highly effective inhibition of SARS-CoV2 infection can be reduced.

**Inhibitory effect of CHPV and Suramin on SARS-CoV-2 virus infection.**

Given that both CHPV and suramin are able to block the SARS-CoV2-SP pseudovirus entry, we next tested whether these two drugs could block wild type SARS-CoV2 virus infection and virus-induced cytopathic effect in Vero cells. The wild type SARS-CoV-2 virus (hCoV- 19/Canada/ON-VIDO-01/2020) was used to infect Vero cells in the presence of different concentrations of CHPV or Suramin. Briefly, Vero cells were infected with SARS-CoV-2 (MOI of 0.01) in the presence of different concentrations of CHPV or Suramin. After 72 hrs post-infection, as indicated (Fig. 6), the SARS-CoV-2-induced cytopathic effects in Vero cells were monitored. Results showed that SARS-CoV-2 infection causes dramatic cytopathic effect (CPE) in Vero cells after 72 hrs post-infection, with cells displaying 100% CPE. Remarkably, in the presence of CHPV or suramin (at 50 to 125 µg/ml), the SARS-CoV-2-induced cytopathic effect (CPE) was significantly or completely inhibited in Vero cells. These results provide strong evidence that the presence of CHPV or Suramin is able to inhibit SARS-COV-2 infection.

## Discussion

Because SARS-COV-2 is classified as an aerosol biosafety level 3 (BSL-3) pathogen, the study of SARS-COV-2 infection and the investigation of different anti-SARS-COV-2 compounds required highly restricted BSL-3 containment. This condition has significantly limited the SARS-COV-2-related research activities in microbiology laboratories. In this study, we established a highly sensitive SARS-COV-2-SP psedotyped HIV-based entry system, which encodes a Gaussia luciferase (Gluc) gene as a reporter (Fig. 1B). Since Gluc can be secreted into the supernatant after being expressed in the infected cells, it is very sensitive and convenient for evaluating the level of SARS-CoV2-SP-mediated virus entry and may be used for anti-SARS-CoV2-SP compound screening in a BSL-2 environment.

Previous studies have revealed that the cytoplasmic tail (CT) of SARS SP contains a dibasic motif (KxHxx) that constitutes for an endoplasmic reticulum (ER) retrieval signal which retains the full-length SARS-S protein in the lumen of the ER-Golgi intermediate compartment (ERGIC) [39,40]. Deletion of 17 aa at the carboxyl-terminal in the CT of SARS SP was able to increase SP transported to the surface of cells and substantially increased SARS SP-mediated cell-to-cell fusion [37]. In the SARS-CoV2-SP, there is also a dibasic motif (KxHxx) present in the CT (Fg 1A). In order to increase SARS-CoV2-SP incorporation into pseudovirions, we have deleted 17 aa at the CT of SARS-CoV2 SP and generated a SARS-CoV2 SPΔC expressor plasmid (Fig. 1A, b). Indeed, our data showed that a significantly higher level of SCoV2 SPΔC protein was present in the pseudovirus (Fig. 1C), and induced remarkably efficient infection in $293T_{ACE2}$ cells (Fig. 1D). This observation clearly indicate that the dibasic motif in SARS-COV-2 SP is functional and a deletion of 17 amino acids substantially increased incorporation of SP into SARS-CoV2-SP-PVs and enhance its infectivity. This information is also important for improving the design of SARS-CoV2-SP-based vaccine strategies.

Recent sequencing analyses found a SARS-CoV2 SP mutation, Aspartic acid (D) changed to Glycine (G) at aa position 614 in the S1 domain which was dominantly detected in April to May of 2020 isolates, indicating a transmission advantage over original SP D614 [15]. The following studies showed that SARS-$CoV2_{G614}$ SP mutant MLV pseudotyped viruses infected ACE2-expressing cells markedly more efficiently than those with SARS-$CoV2_{D614}$ [16,41]. Consistently, we also observed the SARS-$CoV2_{G614}$ΔC-pseudotyped lentiviral particles enhanced the pseudotyped virus entry compared to the $SP_{D614}$ΔC-PVs (Fig. 2E).

By using this SCoV2-SP- pseudovirus system, we have provided evidence for the first time that the CHPV can efficiently prevent infections mediated by both SARS-CoV2-$SP_{D614}$ and -$SP_{G614}$ pseudovirus infection in $293T_{ACE2}$ cells and significantly block the infection of wildtype SARS-COV-2 in Vero cells. We also revealed that CHPV blocks the entry of virus by directly interrupting the interaction of SARS-CoV2-SP and ACE2 receptor by *in vitro* ELISA assay (Fig. 4 ). Interestingly,

the presence of CHPV at one hour post-infection is still able to efficiently inhibit SARS-Cov2-SP pseudovirus infection (Fig. 4), suggesting that CHPV may not only target SP/ACE2 binding, but may also act on the following fusion step(s). Overall, our results provide convincing evidence for CHPV as a potential blocking agent against SARS-COV-2 infection. In agreement with a recent study [33] that suramin can inhibit SARS-COV-2 virus infection, we further provide evidence that suramin is able to directly block SARS-CoV-2 SP-ACE2 interaction (Fig. 4D) and different SARS-CoV-2 SP variants mediated virus entry (Fig 3, 4, and 5).

Another interesting observation in this study is that the combination of CHPV or suramin with anti-SARS-COV-2 neutralizing antibody (nAb) could enhance their anti-SARS-COV-2 activity. The nAb has great potential to be used as a preventing agent in blocking SARS-COV-2 infection [42]. However, one disadvantage of using nAb as an anti-SARS-COV-2 agent is its source limitation. Therefore, the finding of the synergistic effect of a combination of nAb with other agents, such as CHPV or Suramin is beneficial for (i) similar efficiencies would be achieved by using reduced amounts of antibody and CHPV or Suramin, (ii) the combination of nAb and CHPV/suramin will reduce the likelihood of viral resistance. Whether these enhanced effects might be due to a combined effect through their different binding mechanisms still needs to be investigated.

The effectiveness of CHPV and/or suramin against SARS-COV-2 infection *in vivo* remains to be investigated. Our findings could be further validated in an appropriate animal model and clinical trials for prevention of COVID-19. Since SARS-COV-2 infection initiates in the respiratory tract [43], the use of CHPV and/or Suramin as nasopharynx agents (Nasal spray) to prevent initial SARS-COV-2 infection and transmission in the respiratory tract will be a particularly attractive strategy, and will require further efficacy studies. Overall, we demonstrated that CHPV and suramin possess an anti-SARS-COV-2 entry inhibitor activity and functions at least partially by interrupting SARS-COV-2 SP binding to its receptor. Additional *in vivo* safety and protection studies will facilitate its application as an option to help control the ongoing SARS-CoV-2 pandemic.

**Acknowledgements:**

Dr. X-j Yao holds a Manitoba Research Chair Award from the Research Manitoba. O.T.A is the recipient of PhD scholarship from the Research Manitoba/Manitoba Institute of Child Health. This work was supported by Canadian 2019 Novel Coronavirus (COVID-19) Rapid Research Funding (OV5-170710) by Canadian Institute of Health Research (CIHR) and Research Manitoba.

# References


1. Li Q, Guan X, Wu P, Wang X, Zhou L, et al. (2020) Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med 382: 1199-1207.
2. Abdollahi E, Champredon D, Langley JM, Galvani AP, Moghadas SM (2020) Temporal estimates of case-fatality rate for COVID-19 outbreaks in Canada and the United States. CMAJ 192: E666-E670.
3. Li Q, Guan X, Wu P, Wang X, Zhou L, et al. (2020) Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-"Infected Pneumonia. New England Journal of Medicine.
4. Baud D, Qi X, Nielsen-Saines K, Musso D, Pomar L, et al. (2020) Real estimates of mortality following COVID-19 infection. Lancet Infect Dis 20: 773.
5. Organization WH (2020) Estimating mortality from COVID-19 Scientific brief, 4 August 2020. https://wwwwhoint/publications/i/item/WHO-2019-nCoV-Sci-Brief-Mortality-20201.
6. Zhang Y-Z (2020) Severe acute respiratory syndrome coronavirus 2 isolate Wuhan-Hu-1, complete genome. GenBank: MN9089473.
7. Zhou Z, Kang H, Li S, Zhao X (2020) Understanding the neurotropic characteristics of SARS-CoV-2: from neurological manifestations of COVID-19 to potential neurotropic mechanisms. J Neurol 267: 2179-2184.
8. Ahmed MU, Hanif M, Ali MJ, Haider MA, Kherani D, et al. (2020) Neurological Manifestations of COVID-19 (SARS-CoV-2): A Review. Front Neurol 11: 518.
9. Kim GU, Kim MJ, Ra SH, Lee J, Bae S, et al. (2020) Clinical characteristics of asymptomatic and symptomatic patients with mild COVID-19. Clin Microbiol Infect 26: 948 e941-948 e943.
10. Lin L, Jiang X, Zhang Z, Huang S, Zhang Z, et al. (2020) Gastrointestinal symptoms of 95 cases with SARS-CoV-2 infection. Gut 69: 997-1001.
11. Raj VS, Osterhaus ADME, Fouchier RAM, Haagmans BL (2014) MERS: emergence of a novel human coronavirus. Current opinion in virology 5: 58-62.
12. Su S, Wong G, Shi W, Liu J, Lai ACK, et al. (2016) Epidemiology, genetic recombination, and pathogenesis of coronaviruses. Trends in microbiology 24: 490-502.
13. Lu R, Zhao X, Li J, Niu P, Yang B, et al. (2020) Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet Jan 30 S0140-6736(0120)30251-30258.
14. Jaimes JA, Millet JK, Whittaker GR (2020) Proteolytic Cleavage of the SARS-CoV-2 Spike Protein and the Role of the Novel S1/S2 Site. iScience 23: 101212.
15. Korber B. FW, Gnanakaran S., Yoon H., Theiler J., Abfalterer W., Foley B., Giorgi EE., Bhattacharya T., Parker MD., Partridge DG., Evans CM., Freeman TM., de Silva TI, LaBranche C.C., and Montefiori DC. (2020) Spike mutation pipeline reveals the emergence of a more transmissible form of SARS-CoV-2. bioRxiv https://doi.org/10.1101/2020.04.29.069054.
16. Lizhou Zhang CBJ, Huihui Mou, Amrita Ojha, Erumbi S Rangarajan, Tina Izard, Michael Farzan, Hyeryun Choe (2020) The D614G mutation in the SARS-CoV-2 spike protein reduces S1 shedding and increases infectivity bioRxiv 06.12.: 148726.
17. Cao B, Wang Y, Wen D, Liu W, Wang J, et al. (2020) A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med 382: 1787-1799.
18. Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, et al. (2020) Compassionate use of remdesivir for patients with severe Covid-19. New England Journal of Medicine 382: 2327-2336.
19. Zhang L, Lin D, Sun X, Curth U, Drosten C, et al. (2020) Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved Î±-ketoamide inhibitors. Science 368: 409-412.
20. Huang D, Yu H, Wang T, Yang H, Yao R, et al. (2020) Efficacy and safety of umifenovir for coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis. J Med Virol.

21. Wang M, Cao R, Zhang L, Yang X, Liu J, et al. (2020) Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 30: 269-271.
22. Hussain S, Xie YJ, Li D, Malik SI, Hou JC, et al. (2020) Current strategies against COVID-19. Chin Med 15: 70.
23. Park S-J, Yu K-M, Kim Y-I, Kim S-M, Kim E-H, et al. (2020) Antiviral Efficacies of FDA-Approved Drugs against SARS-CoV-2 Infection in Ferrets. Mbio 11.
24. Zheng M (1990) [Experimental study of 472 herbs with antiviral action against the herpes simplex virus]. Zhong xi yi jie he za zhi= Chinese journal of modern developments in traditional medicine/Zhongguo Zhong xi yi jie he yan jiu hui (chou), Zhong yi yan jiu yuan, zhu ban 10: 39-41, 36.
25. Yao XJ, Wainberg MA, Parniak MA (1992) Mechanism of inhibition of HIV-1 infection in vitro by purified extract of Prunella vulgaris. Virology 187: 56-62.
26. Zhang X, Ao Z, Bello A, Ran X, Liu S, et al. (2016) Characterization of the inhibitory effect of an extract of Prunella vulgaris on Ebola virus glycoprotein (GP)-mediated virus entry and infection. Antiviral Res 127: 20-31.
27. Liu S, Jiang S, Wu Z, Lv L, Zhang J, et al. (2002) Identification of inhibitors of the HIV-1 gp41 six-helix bundle formation from extracts of Chinese medicinal herbs Prunella vulgaris and Rhizoma cibotte. Life Sci 71: 1779-1791.
28. Xu HX, Lee SH, Lee SF, White RL, Blay J (1999) Isolation and characterization of an anti-HSV polysaccharide from Prunella vulgaris. Antiviral Res 44: 43-54.
29. De Clercq E (1987) Suramin in the treatment of AIDS: mechanism of action. Antiviral Res 7: 1-10.
30. Cheson BD, Levine AM, Mildvan D, Kaplan LD, Wolfe P, et al. (1987) Suramin therapy in AIDS and related disorders. Report of the US Suramin Working Group. JAMA 258: 1347-1351.
31. Yao XJ, Wainberg MA, Pollak M (1991) The inhibitory effects of suramin on HIV-1 are attenuated in the presence of albumin. AIDS 5: 1389-1391.
32. Kuo SC, Wang YM, Ho YJ, Chang TY, Lai ZZ, et al. (2016) Suramin treatment reduces chikungunya pathogenesis in mice. Antiviral Res 134: 89-96.
33. Clarisse Salgado Benvindo da Silva MT, Ali Tas, Natacha S. Ogando, Peter J. Bredenbeek, Dennis K. Ninaber, Ying Wang, Pieter S. Hiemstra, Eric J. Snijder, Martijn J. van 6 Hemert (2020) Suramin inhibits SARS-CoV-2 infection in cell culture by interfering 1 with early steps of the replication cycle. bioRxiv May: https://doi.org/10.1101/2020.1105.1106.081968.
34. Ao Z, Huang J, Tan X, Wang X, Tian T, et al. (2016) Characterization of the single cycle replication of HIV-1 expressing Gaussia luciferase in human PBMCs, macrophages, and in CD4(+) T cell-grafted nude mouse. J Virol Methods 228: 95-102.
35. Qiu X, Alimonti JB, Melito PL, Fernando L, Ströher U, et al. (2011) Characterization of Zaire ebolavirus glycoprotein-specific monoclonal antibodies. Clinical immunology 141: 218-227.
36. Ao Z, Huang G, Yao H, Xu Z, Labine M, et al. (2007) Interaction of human immunodeficiency virus type 1 integrase with cellular nuclear import receptor importin 7 and its impact on viral replication. Journal of Biological Chemistry 282: 13456-13467.
37. Petit CM, Melancon JM, Chouljenko VN, Colgrove R, Farzan M, et al. (2005) Genetic analysis of the SARS-coronavirus spike glycoprotein functional domains involved in cell-surface expression and cell-to-cell fusion. Virology 341: 215-230.
38. Jarek Juraszek LR, Sven Blokland, Pascale Bouchier, Richard Voorzaat, Tina Ritschel, Mark J.G. Bakkers, Ludovic L.R. Renault, Johannes P.M. Langedijk (2020) Stabilizing the Closed SARS-CoV-2 Spike Trimer bioRxiv https://doi.org/10.1101/2020.07.10.197814doi:: July 10.
39. Sadasivan J, Singh M, Sarma JD (2017) Cytoplasmic tail of coronavirus spike protein has intracellular targeting signals. J Biosci 42: 231-244.

40. McBride CE, Li J, Machamer CE (2007) The cytoplasmic tail of the severe acute respiratory syndrome coronavirus spike protein contains a novel endoplasmic reticulum retrieval signal that binds COPI and promotes interaction with membrane protein. J Virol 81: 2418-2428.

41. Jie Hu C-LH, Qing-Zhu Gao, Gui-Ji Zhang, Xiao-Xia Cao, Quan-Xin Long, Hai-Jun Deng, Lu-Yi Huang, Juan Chen, Kai Wang, Ni Tang, Ai-Long Huang (2020) The D614G mutation of SARS-CoV-2 spike protein enhances viral infectivity 1 and decreases neutralization sensitivity to individual convalescent sera bioRxiv https://doi.org/10.1101/2020.06.20.161323doi: .

42. Jiang S, Hillyer C, Du L (2020) Neutralizing antibodies against SARS-CoV-2 and other human coronaviruses. Trends in immunology.

43. Wolfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, et al. (2020) Virological assessment of hospitalized patients with COVID-2019. Nature 581: 465-469.




**Figure 1. Generation of a SARS-COV2-SP-pseudotyped lentiviruse particles (SCoV-2-SP-PVs)**. A) Schematic representation of SARS-CoV-2SP, SARS-CoV-2SPΔC, and SARS-CoV-2SP$_{G614}$ΔC expressing plasmids. B) Schematic representation of plasmids and and procedures for production of SARS-COV2-SP-pseudotyped lentivirus particles (SCoV-2-SP-PVs). C) Detection of SARS-CoV-2 SPs and HIV p24 protein expression in transfected 293T cells and viral particles by Western blot (WB) with anti-SP or anti-p24 antibodies. D) Different amounts of SCoV-2-SP-PVs and SCoV-2-SPΔC-PVs virions (adjusted by p24) were used to infect 293T$_{ACE2}$ cells. At different time intervels, the Gaussia Luciferase activity (Gluc) (left panel) and PVs-associated p24 (at 72 hrs) in supernatants was measured.




**Figure 2. SARS-CoV-2 SP-PVs's infection in different cell lines and SARS-CoV-2 SP$_{G614}$ variant exhibited stronger virus entry.** A) 293T, 293T$_{ACE2}$ and Vero-E6 cells were infected by equal amounts of SARS-CoV-2SP-, SARS-CoV-2SPΔC-pseudotyped viruses. At 48 hrs pi, the Gluc activity in supernatants was measured. B) the expression of SARS-CoV-2SP receptor, ACE2, in 293T, 293T$_{ACE2}$ and Vero-E6 cells detected by WB with anti-ACE2 antibodies. C) The SPΔC$_{G614}$-GFP$^{+}$PVs were produced with 293T cells and used to infect 293T$_{ACE2}$ cells in 96-well plate After 48 hrs pi, GFP-positive cells (per well) were counted and photographed by fluorescence microscope (on the top of the panel). D) Detection of SARS-CoV-2 SPΔC, SPΔC$_{G614}$ and HIV p24 protein expression in transfected 293T cells and viral particles by WB. E) Infectivity comparison of SPΔC-PVs and SPΔC$_{G614}$-PVs in 293T$_{ACE2}$ cells. Equal amounts of SPΔC$_{D614}$-PVs and SPΔC$_{G614}$-PVs virions (adjusted by p24 level) were used to infect 293T$_{ACE2}$ cells. At different days post-infection (pi), Gluc activity in supernatants was measured.




**Figure 3. SARS-CoV-2-SP-PV's infection was efficiently blocked by CHPV and suramin.** A) Images of the dried Prunella Vulgaris flowers and its water extract (CHPV). B) Dose -response anti-SARS-CoV-2 analysis by Gluc activity for CHPV or suramin. 293T$_{ACE2}$ cells were infected by equal amounts of SARS-CoV-2SPΔC-pseudotyped viruses in the presence of different dose of CHPV or suramin. At 48 hrs pi, the Gluc activity in supernatants was measured. (% inhibition = 100 x [1 - (Gluc value in presence of drug)/(Gluc value in absence of drug)). C) Infection inhibition of CHPV or suramin on SARS-CoV-2-SPΔC$_{G614}$-PVs in 293T$_{ACE2}$ cells. Equal amounts of SCoV-2-SPΔC$_{G614}$-PVs (adjusted by p24 level) were used to infect 293T$_{ACE2}$ cells in presence of different concentrations of CHPV or suramin, in indicated at bottom of the panel. At 48 hrs pi, Gluc activity in supernatants was measured and present as % inhibition. Means ± SD were calculated from duplicate experiments. D) 293T$_{ACE2}$ cells in 96-well plate were infected with SPΔC$_{G614}$-GFP$^+$ PVs. After 48 hrs pi, GFP-positive cells (per well) were counted (left panel) and photographed by fluorescence microscope (right panel, a. Without drugs; b. Without infection; c. In the presence of CHPV (100 μg/ml**)**; d. In the presence of suramin (100 μg/ml**)**.




**Figure 4. Characterization of the mechanisms of CHPV and suramin for their anti-SARS-COV-2-SP action.** A) Time-dependent inhibition of SPΔ$C_{G614}$-PVs infection mediated by CHPV or suramin. CHPV (100 µg/mL) or suramin (100 µg/mL) was added at 1 hr prior to infection, during infection (0 hr), and at 1 hr, and 3 hr pi. The positive controls (PC) were 293$T_{ACE2}$ cells infected with SPΔ$C_{G614}$-PVs in the absence of compounds. At 3 hrs pi, all of the cell cultures were replaced with fresh DMEM and cultured for 48 hrs. Then, the Gluc activity was monitored in the supernatant, and the data are shown as a percentage of inhibition (%). B) inhibitory effect of CHPV or suramin on SARS-CoV2-SP/ACE2 binding by ELISA as described in materials and methods. nAB: anti-COVID-19 neutralizing antibody (SAD-S35). The results are the mean ± SD of duplicate samples, and the data are representative of results obtained in two independent experiments.




**Figure 5. Enhanced inhibitory effects mediated by combination of CHPV and suramin with neutralizing antibody (SAD-S35).** A) 293T$_{ACE2}$ cells were infected with SPΔC$_{G614}$-PVs in presence of CHPV (50μg/ml) or suramin (50μg/ml) alone or a mix of CHPV and suramin (each with 25μg/ml). After 3 hrs of infection, cells were washed and add fresh medium for 48 hrs. Then the supernatants were collected and Gluc activity in the supernatant was measured and present as % inhibition. B) Inhibitory effect of nAb SAD-S35 on SPΔC$_{G614}$-PVs infection. 293T$_{ACE2}$ cells were infected with SPΔC$_{G614}$-PVs in the presence of serially diluted SAD-S35 (1.25 to 10 μg/ml) for 3 hrs. Then infected cells were cultured in fresh medium. At 48 hrs pi., the supernatants were collected and measured for Gluc activities and presented as % inhibition. C) 293T$_{ACE2}$ cells were infected with SPΔC$_{G614}$-PVs in the presence of serially diluted SAD-S35 (0.625 to 2.5 μg/ml) alone or mixed with CHPV (25 μg/mL) or Suramin (25 μg/mL) for 3 hrs and the infected cells were cultured in fresh medium. At 48 hrs pi., the Gluc activities in the supernatants were measured and presented as % inhibition. The results are the mean ± SD of duplicate samples, and the data are representative of results obtained in two independent experiments.




**Figure 6. Inhibitory effect of CHPV and Suramin on SARS-CoV-2 infection-induced cytopathic effects.** Vero cells were infected with a wild type *SARS-CoV-2* virus (hCoV-19/Canada/ON-VIDO-01/2020) in the presence or absence of different concentrations of CHPV and Suramin. After 72 hrs pi., the SARS-CoV-2 infection-induced cytopathic effects in Vero cells were monitored. Error bars represent variation between triplicate samples, and the data of (A) and (B) are representative of results obtained in two independent experiments.